

FREEDOM IS NOT  
AN OPTION.

HENZ

MAKE A CHOICE AND MANAGE DIABETES

With,

## DAPAHENZ-S 10/100

Dapagliflozin 10 mg + Sitagliptin 100 mg Tablets

## DAPAHENZ-S 10/50

Dapagliflozin 10 mg + Sitagliptin 50 mg Tablets

## DAPAHENZ-S 5/100

Dapagliflozin 5 mg + Sitagliptin 100 mg Tablets

## DAPAHENZ-S 5/50

Dapagliflozin 5 mg + Sitagliptin 50 mg Tablets

# DAPAHENZ-S 10/100

Dapagliflozin 10 mg + Sitagliptin 100 mg Tablets

# DAPAHENZ-S 5/100

Dapagliflozin 5 mg + Sitagliptin 100 mg Tablets

# DAPAHENZ-S 10/50

Dapagliflozin 10 mg + Sitagliptin 50 mg Tablets

# DAPAHENZ-S 5/50

Dapagliflozin 5 mg + Sitagliptin 50 mg Tablets

## BACKGROUND:

The incidence of type 2 diabetes mellitus (T2DM) is rapidly increasing often resulting in significant metabolic disorders and severe complications. Cardiovascular (CV) risk reduction in T2DM is of utmost importance to reduce the risk of CV morbidity and mortality. A “pathophysiological approach” using initial combination therapy with agents known to address the established defects in T2DM seems more rational. Reported evidence with SGLT2i and several clinical trials of DPP4i have demonstrated that these agents reduce glycaemic variability in patients with T2DM. Dapagliflozin added to Sitagliptin been reported to have additional clinical benefit and demonstrated well tolerated profile in patients with inadequately controlled T2DM.

## DESCRIPTION:

**DAPAHENZ-S 10/50, 10/100** : is a film coated tablet contains Dapagliflozin 10 mg and Sitagliptin 50/100 mg .

**DAPAHENZ-S 5/50, 5/100** : is a film coated tablet contains Dapagliflozin 5 mg and Sitagliptin 50/100 mg.

## INDICATION:

As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

## MECHANISM OF ACTION:

### Dapagliflozin:

- ✓ By inhibiting SGLT2, Dapagliflozin blocks reabsorption of filtered glucose in the kidney, increasing urinary glucose excretion and reducing blood glucose levels.
- ✓ This excretion allows for better glycemic control and potentially weight loss in patients with type 2 diabetes mellitus.

### Sitagliptin:

- ✓ Sitagliptin prolongs the action of GLP-1 and GIP.
- ✓ By enhancing active incretin levels, sitagliptin increases insulin production and lowers glucagon secretion from alpha cells, which decreases hepatic glucose overproduction.

## DOSAGE AND ADMINISTRATION:

- ✓ **DAPAHENZ-S**: Once daily Orally or as prescribed by the doctor.

\*GLP-1= glucagon-like peptide-1; GIP= glucose-dependent insulinotropic polypeptide

Reference: Diabetes

Care 2014;37:740-750 | DOI: 10.2337/dc13-0467

L Ravikumar, et al., Cardiol Cardiovasc Med 2023



Scan For More  
Prescribing Information

## La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,

S.G. Highway, Ahmedabad-380015, Gujarat, India.

Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998

E-mail: info@larenon.com | Web: www.larenon.com

I am: \_\_\_\_\_  
Call me on: \_\_\_\_\_  
Mail me at: \_\_\_\_\_

©2025 All Rights Reserved, La Renon Healthcare Private Limited